• Skip to primary navigation
  • Skip to main content
SRI logo
  • About
    • Press room
    • Our history
  • Expertise
    • Advanced imaging systems
    • Artificial intelligence
    • Biomedical R&D services
    • Biomedical sciences
    • Computer vision
    • Cyber & formal methods
    • Education and learning
    • Innovation strategy and policy
    • National security
    • Ocean & space
    • Quantum
    • Robotics, sensors & devices
    • Speech & natural language
    • Video test & measurement
  • Ventures
  • NSIC
  • Careers
  • Contact
  • 日本支社
Search
Close
Press release January 5, 2022

SRI International announces collaboration agreement with Janssen

MENLO PARK, Calif., Jan. 5, 2022 /PRNewswire/ — SRI International (SRI) today announced the company has entered into a collaboration agreement with Janssen Pharmaceutica NV (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Under the terms of the agreement, the organizations and their scientists will leverage SRI’s SynFini™ platform, an artificial intelligence (Al)-guided, automated synthetic- chemistry system for small molecule drug discovery. The agreement was facilitated by Johnson & Johnson Innovation.

SRI’s SynFini platform combines Al and automation to accelerate small-molecule drug discovery and development. The platform is comprised of four components (DASL™ SynRoute™  SynJet™ and AutoSyn™) that work seamlessly together to automate the design of molecules and the synthetic routes to make them, reaction screening and optimization (RSO), and production of target molecules.

“Through both SRI-driven programs and a growing number of collaborations with leading pharmaceutical and biotechnology strategic partners, the SynFini platform is demonstrating the ability to use Al and automation to combine complex design with rapid synthesis and testing to overcome many of the constraints of traditional drug discovery,” said Nathan Collins, Ph.D., chief strategy officer of SRI’s Biosciences Division and head of the SynFini program. “We are excited to be working with the exceptional scientists at Janssen in the application and further development of this novel platform.”

The SynFini platform is designed to accelerate the “design-make -test” cycle of multi-parametric optimization in small molecule hit-to-lead and lead optimization. Streamlining these steps with a highly data-driven process in drug discovery has the potential to bring new drugs to the patients who need them faster and more cost-effectively.

SRI International

SRI International creates world-changing solutions making people safer, healthier and more productive. SRI, a research center headquartered in Menlo Park, California, works primarily in advanced technology and systems, biosciences, computing and education. SRI brings its innovations to the marketplace through technology licensing, spin-off ventures and new product solutions.

Share this
Career call to action image

Work with us

Search jobs

How can we help?

Once you hit send…

We’ll match your inquiry to the person who can best help you.

Expect a response within 48 hours.

Our work

Case studies

Publications

Timeline of innovation

Areas of expertise

Institute

Leadership

Press room

Media inquiries

Compliance

Careers

Job listings

Contact

SRI Ventures

Our locations

Headquarters

333 Ravenswood Ave
Menlo Park, CA 94025 USA

+1 (650) 859-2000

Subscribe to our newsletter


日本支社
SRI International
  • Contact us
  • Privacy Policy
  • Cookies
  • DMCA
  • Copyright © 2023 SRI International
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}